QV Investors Inc. Invests $7.77 Million in Hims & Hers Health, Inc. $HIMS

QV Investors Inc. bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 224,130 shares of the company’s stock, valued at approximately $7,771,000. QV Investors Inc. owned approximately 0.10% of Hims & Hers Health at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. State Street Corp boosted its position in shares of Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after acquiring an additional 132,311 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after acquiring an additional 608,950 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after acquiring an additional 2,877,550 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after acquiring an additional 1,600,004 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $28.88 on Monday. The stock has a market cap of $6.74 billion, a P/E ratio of -45.84 and a beta of 2.40. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The stock has a 50 day moving average of $32.14 and a two-hundred day moving average of $26.40. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter last year, the business posted $0.17 earnings per share. The business’s revenue was up 38.2% on a year-over-year basis.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to attract attention for its expansion in telehealth and weight-loss treatments. Recent analysis highlights the company’s broader growth opportunity, while second-quarter revenue rose 38.2% year over year to $753.2 million, exceeding expectations. Hims & Hers Is Growing Into Something Much Bigger
• Neutral Sentiment: Chief Executive Officer Andrew Dudum pushed back against the Federal Trade Commission’s position, arguing that the agency does not fully understand Hims & Hers’ business. The dispute may shape investor views of the company’s ability to defend its practices and continue operating its weight-loss platform. Hims & Hers CEO Says the FTC Doesn’t Understand His Own Company
• Negative Sentiment: Visa reportedly placed Hims & Hers in its Acquirer Monitoring Program after a rise in credit-card billing disputes. Potential penalties or increased payment-processing scrutiny could raise costs and pressure the company’s already declining gross margin. Hims & Hers Weight-Loss Plans Results Penalties Over Visa Credit Card Disputes
• Negative Sentiment: Separate reports describe FTC scrutiny involving health-data sharing and tracking tools. Regulatory action could increase compliance costs, limit marketing practices or damage customer trust. FTC Targets Hims & Hers Over Health Data Sharing
• Negative Sentiment: Kaplan Fox and Pomerantz announced investigations into potential violations of federal securities laws. These announcements do not establish wrongdoing, but they add legal uncertainty, potential costs and headline risk for shareholders. Kaplan Fox Investigation Pomerantz Investor Investigation
• Negative Sentiment: The company’s latest quarterly results showed an adjusted earnings shortfall despite the revenue beat, reinforcing concerns about profitability and valuation as regulatory and operating pressures increase. Unpacking Q2 Earnings

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47. Following the transaction, the chief financial officer directly owned 228,938 shares in the company, valued at approximately $8,033,434.42. The trade was a 19.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Deborah M. Autor sold 16,773 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the sale, the insider directly owned 48,961 shares of the company’s stock, valued at $1,363,563.85. The trade was a 25.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 186,769 shares of company stock worth $6,035,648 in the last three months. Company insiders own 11.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Citigroup cut their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Barclays lowered their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, August 21st. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. cut their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $32.50.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.